CHICAGO (Reuters) - A panel of federal vaccine experts narrowly voted to add a booster dose of a meningitis vaccine to teens at age 16.
The Advisory Committee on Immunization Practices voted 6-5 on Wednesday to add a booster dose of the vaccine at age 16 to address waning immunity among older teens against meningococcal bacteria that causes meningitis. Three members abstained.
The CDC already recommends routine meningitis vaccination beginning at age 11. The vote affects Sanofi Aventis, maker of a vaccine called Menactra, and Novartis, which in February won U.S. approval for its vaccine called Menveo to protect people aged 11 to 55.
The committee advises the U.S. Centers for Disease Control and Prevention.
Reporting by Julie Steenhuysen; Editing by Lisa Von Ahn